![Man ultramarathon runner in the mountains he trains at sunset](https://d2csxpduxe849s.cloudfront.net/media/E32629C6-9347-4F84-81FEAEF7BFA342B3/0B4B1380-42EB-4FD5-9D7E2DBC603E79F8/webimage-C4875379-1478-416F-B03DF68FE3D8DBB5.png)
94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
CORRECTION article
Front. Pharmacol. , 12 July 2021
Sec. Ethnopharmacology
Volume 12 - 2021 | https://doi.org/10.3389/fphar.2021.730775
This article is a correction to:
Tubeimoside 1 Acts as a Chemotherapeutic Synergist via Stimulating Macropinocytosis
A corrigendum on
Tubeimoside 1 Acts as a Chemotherapeutic Synergist via Stimulating Macropinocytosis
by Gong, X., Sun, R., Gao, Z., Han, W., Liu, Y., Zhao, L., Jing, L., Yao, X., and Sun X. (2018). Front. Pharmacol. 9:1044. doi:10.3389/fphar.2018.01044
In the original article, there was a mistake in Figure 6 as published.
FIGURE 6. Chloroquine suppress TBM1-induced vacuolation and cell death in CRC cells. (A) SW480 were treated with 8 μM TBM1 for different time or starvation or 1 μM rapamycin for 24 h. Protein expression of LC3-I and LC3-II was detected by Western blotting. Beta-actin were served as loading control. (B) SW480 cells were pre-cultured with or without chloroquine (CQ) (10 μM) for 1 h before exposure to TBM1 for 24 h. LC3 processing was assessed using Western blotting analysis. (C) After treatment with SW480 cells for different time as (B), morphological changes were observed by phase-contrast microscopy. (D) SW480 cells were pre-cultured with or without 3-MA (3 mM) for 1 h before exposure to TBM1 for different time. Morphological changes were observed using phase-contrast microscopy. (E) The number of vacuoles of the same cultures as (B) for 48 h was counted from three different imagines. (F) Cell viability was measured by MTT assay (n = 5). #p < 0.01.
The second image of bottom panel of Figure 6D was misused. The corrected Figure 6 appears below.
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Keywords: tubeimoside 1, chemotherapeutic synergist, macropinocytosis, methuosis, endocytosis
Citation: Gong X, Sun R, Gao Z, Han W, Liu Y, Zhao L, Jing L, Yao X and Sun X (2021) Corrigendum: Tubeimoside 1 Acts as a Chemotherapeutic Synergist via Stimulating Macropinocytosis. Front. Pharmacol. 12:730775. doi: 10.3389/fphar.2021.730775
Received: 25 June 2021; Accepted: 28 June 2021;
Published: 12 July 2021.
Approved by:
Frontiers Editorial Office, Frontiers Media SA, SwitzerlandCopyright © 2021 Gong, Sun, Gao, Han, Liu, Zhao, Jing, Yao and Sun. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Xuegang Sun, c3hnX3NtdUAxMjYuY29t
†These authors have contributed equally to this work
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Research integrity at Frontiers
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.